Blood cancer molecular assays

Blood cancer molecular assays
ALL (1)
10%
Acute lymphoblastic leukemia
MPN (1, 2)
39%
CLL (1)
Myeloproliferative neoplasms
27%
Chronic lymphocytic leukemia
AML (1)
24%
Myeloid
MPN
Polycythemia vera, 41%
(JAK2 V617F, 96%)
Chronic myeloid
leukemia
t(9;22), 24%
(BCR-ABL1, 95%)
Acute myeloid leukemia
Lymphoid
AML
Complex
karyotype t(8;21)
abn(11q23) 4% 3%
4%
inv(16)
5%
CLL
Normal
karyotype
45%
abn(14q32)
4%
+8q24
5%
del(17p)
7%
ALL
del(6q)
3%
t(10;14)
t(11;14) 5%
del(13q)
48%
abn(12p13)
3.5%
6%
abn(12q23)
6,5%
t(9;22)
24%
tri(8)
6%
Diseases
and genetic
abnormalities
del(11q22
-q23)
14%
t(15;17)
7%
del(17q)
8%
Other
13%
Essential thrombocythemia,
22%
(JAK2 V617F, 55%)
Idiopathic
myelofibrosis, 13%
(JAK2 V617F, 65%)
tri(12)
19%
abn chr 5&7
13%
Diagnosis and
prognosis
biomarkers
BCR-ABL1 mutations
BCR-ABL1
JAK2 mutations
MPL mutations
PML-RARA
RAS
EVI1
BAALC
MN1
NPM1 mutations
WT1
FLT3 (ITDs or mutations)
CEBPα
MLL-partner genes
RUNX1-RUNX1T1
CBFb-MYH11
Follow-up
biomarkers
BCR-ABL1
JAK2 V617F
PML-RARA
MLL-partner genes
CBFb-MYH11
RUNX1-RUNX1T1
WT1
Targeted therapies
and other treatments
Imatinib mesylate
(Gleevec®)
Dasatinib (Sprycel®)
Nilotinib (Tasigna®)
Hydroxyurea (Hydrea®)
Interferon
Other treatments
ATRA/Arsenic trioxide
Aurora/FLT3 kinase
inhibitor
Other kinase inhibitors
Farnesyl transferase
inhibitors
Proteasome inhibitors
Immunotargeting
Other treatments
IgVH mutational status
ZAP-70 & CD38
CLLU1
LPL
t(1;14)
20%
del(9q)
11%
Other
15%
BCR-ABL1
MLL-partner genes
ETV6-RUNX1
TCF3-PBX1
SIL-TAL1
BCR-ABL1
MLL-partner genes
ETV6-RUNX1
TCF3-PBX1
SIL-TAL1
Immunotargeting
Anti-BCL2
Other treatments
Imatinib mesylate
(Gleevec®)
Other kinase inhibitors
Immunotargeting
Other treatments
References:
1. Incidence in the USA in 2011. Leukemia and Lymphoma Society Website www.leukemia-lymphoma.org
2. Kutti J., Ridell B. (2001) Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic
myelofibrosis. Pathol Biol 49, 164
Sample & Assay Technologies
Manufacturer: QIAGEN GmbH, QIAGEN Strasse 1, 40724 Hilden, Germany
ipsogen kits are in-vitro diagnostic medical devices validated in molecular biology for the detection and/or
quantification of biomarkers in the diagnosis and follow-up of patients with leukemia.
For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit
handbook or user manual. QIAGEN kit handbooks and user manuals are available at www.qiagen.com
or can be requested from QIAGEN Technical Services or your local distributor.
Fabricant : QIAGEN GmbH, QIAGEN Strasse 1, 40724 Hilden, Allemagne
Les produits ipsogen sont des dispositifs médicaux de diagnostic in vitro validés pour la détection et/ou la
quantification en biologie moléculaire de biomarqueurs impliqués dans le diagnostic et le suivi de patients
atteints de cancers du sang.
Pour obtenir les dernières informations sur la licence et les clauses de responsabilité spécifiques aux
produits, lire attentivement les instructions figurant dans les notices d’utilisation et/ou sur l’étiquetage des
réactifs et dans le manuel d’utilisation du système. Les manuels des kits et manuels d’utilisation QIAGEN
sont disponibles à l’adresse www.qiagen.com ou peuvent être sollicités auprès des Services techniques
QIAGEN ou du distributeur local.
Trademarks: QIAGEN®, ipsogen® (QIAGEN Group); Gleevec®, Tasigna® (Novartis AG); Sprycel®,
Hydrea® (Bristol-Myers Squibb Oncology)
1075398 © 2013 QIAGEN, all rights reserved.